- Home
- CVAC vs TCPC Comparison
CVAC vs TCPC Comparison
Compare CVAC & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- TCPC
- Stock Information
- Founded
- CVAC 2000
- TCPC 2012
- Country
- CVAC Germany
- TCPC United States
- Employees
- CVAC N/A
- TCPC N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- TCPC Finance/Investors Services
- Sector
- CVAC Health Care
- TCPC Finance
- Exchange
- CVAC Nasdaq
- TCPC Nasdaq
- Market Cap
- CVAC 924.3M
- TCPC 767.3M
- IPO Year
- CVAC 2020
- TCPC 2012
- Fundamental
- Price
- CVAC $3.59
- TCPC $9.09
- Analyst Decision
- CVAC Hold
- TCPC Hold
- Analyst Count
- CVAC 3
- TCPC 7
- Target Price
- CVAC $10.00
- TCPC $8.88
- AVG Volume (30 Days)
- CVAC 1.2M
- TCPC 464.7K
- Earning Date
- CVAC 11-12-2024
- TCPC 02-27-2025
- Dividend Yield
- CVAC N/A
- TCPC 19.41%
- EPS Growth
- CVAC N/A
- TCPC N/A
- EPS
- CVAC N/A
- TCPC N/A
- Revenue
- CVAC $70,565,734.00
- TCPC $249,036,775.00
- Revenue This Year
- CVAC $742.57
- TCPC $27.36
- Revenue Next Year
- CVAC N/A
- TCPC N/A
- P/E Ratio
- CVAC N/A
- TCPC N/A
- Revenue Growth
- CVAC 75.11
- TCPC 21.38
- 52 Week Low
- CVAC $2.22
- TCPC $7.71
- 52 Week High
- CVAC $5.28
- TCPC $11.52
- Technical
- Relative Strength Index (RSI)
- CVAC 45.89
- TCPC 54.06
- Support Level
- CVAC $3.70
- TCPC $8.83
- Resistance Level
- CVAC $4.09
- TCPC $9.23
- Average True Range (ATR)
- CVAC 0.22
- TCPC 0.20
- MACD
- CVAC -0.09
- TCPC 0.03
- Stochastic Oscillator
- CVAC 12.05
- TCPC 64.37
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.